{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:30:43Z","timestamp":1777498243066,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Boehringer Ingelheim Pharma GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-33453-1","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T17:53:30Z","timestamp":1766598810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterization of a new specific mPGES-1 inhibitor in cardiovascular system"],"prefix":"10.1038","volume":"15","author":[{"given":"Xinchun","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malarvizhi","family":"Gurusamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Nasseri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Pekcec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongmei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"33453_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.tips.2017.05.008","volume":"38","author":"T Grosser","year":"2017","unstructured":"Grosser, T., Ricciotti, E. & FitzGerald, G. A. The cardiovascular Pharmacology of nonsteroidal anti-inflammatory drugs. Trends Pharmacol. Sci. 38, 733\u2013748 (2017).","journal-title":"Trends Pharmacol. Sci."},{"key":"33453_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/cpt.794","volume":"102","author":"T Grosser","year":"2017","unstructured":"Grosser, T., Theken, K. N. & FitzGerald, G. A. Cyclooxygenase inhibition: pain, inflammation, and the cardiovascular system. Clin. Pharmacol. Ther. 102, 611\u2013622 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"key":"33453_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/14728222.2023.2285785","volume":"27","author":"J Steinmetz-Sp\u00e4h","year":"2023","unstructured":"Steinmetz-Sp\u00e4h, J. & Jakobsson, P. J. The anti-inflammatory and vasoprotective properties of mPGES-1 Inhibition offer promising therapeutic potential. Expert Opin. Ther. Targets. 27, 1115\u20131123 (2023).","journal-title":"Expert Opin. Ther. Targets"},{"key":"33453_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1681\/ASN.2015050528","volume":"27","author":"R Nasrallah","year":"2016","unstructured":"Nasrallah, R., Hassouneh, R. & H\u00e9bert, R. L. PGE2, kidney Disease, and cardiovascular risk: beyond hypertension and diabetes. J. Am. Soc. Nephrol. 27, 666\u2013676 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"33453_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.4155\/ppa.12.90","volume":"2","author":"JK Norberg","year":"2013","unstructured":"Norberg, J. K. et al. Targeting inflammation: multiple innovative ways to reduce prostaglandin E\u2082. Pharm. Pat. Anal. 2, 265\u2013288 (2013).","journal-title":"Pharm. Pat. Anal."},{"key":"33453_CR6","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.4049\/jimmunol.170.9.4738","volume":"170","author":"D Claveau","year":"2013","unstructured":"Claveau, D. et al. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J. Immunol. 170, 4738\u20134744 (2013).","journal-title":"J. Immunol."},{"key":"33453_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.clim.2006.01.016","volume":"119","author":"JY Park","year":"2006","unstructured":"Park, J. Y., Pillinger, M. H. & Abramson, S. B. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin. Immunol. 119, 229\u2013240 (2006).","journal-title":"Clin. Immunol."},{"key":"33453_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/intimm\/dxz021","volume":"31","author":"K Tsuge","year":"2019","unstructured":"Tsuge, K. et al. Molecular mechanisms underlying prostaglandin E2-exacerbated inflammation and immune diseases. Int. Immunol. 31, 597\u2013606 (2019).","journal-title":"Int. Immunol."},{"key":"33453_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.tcm.2011.04.002","volume":"20","author":"M Wang","year":"2010","unstructured":"Wang, M. & FitzGerald, G. A. The cardiovascular biology of microsomal prostaglandin E synthase-1. Trends Cardiovasc. Med. 20, 189\u2013195 (2010).","journal-title":"Trends Cardiovasc. Med."},{"key":"33453_CR10","doi-asserted-by":"publisher","first-page":"14507","DOI":"10.1073\/pnas.0606586103","volume":"103","author":"M Wang","year":"2006","unstructured":"Wang, M. et al. Deletion of microsomal prostaglandin E synthase-1 augments Prostacyclin and retards atherogenesis. Proc. Natl. Acad. Sci. U S A. 103, 14507\u201314512 (2006).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"33453_CR11","doi-asserted-by":"publisher","first-page":"11790","DOI":"10.1073\/pnas.0604400103","volume":"103","author":"Y Ikeda-Matsuo","year":"2006","unstructured":"Ikeda-Matsuo, Y. et al. Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury. Proc. Natl. Acad. Sci. U S A. 103, 11790\u201311795 (2006).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"33453_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1161\/CIRCULATIONAHA.110.973685","volume":"123","author":"M Wang","year":"2011","unstructured":"Wang, M. et al. Microsomal prostaglandin E2 Synthase-1 modulates the response to vascular injury. Circulation 123, 631\u2013639 (2011).","journal-title":"Circulation"},{"key":"33453_CR13","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1161\/CIRCULATIONAHA.107.731398","volume":"117","author":"M Wang","year":"2008","unstructured":"Wang, M. et al. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 117, 1302\u20131309 (2008).","journal-title":"Circulation"},{"key":"33453_CR14","first-page":"391","volume":"13","author":"Q Wang","year":"2021","unstructured":"Wang, Q. et al. Targeting microsomal prostaglandin E synthase 1 to develop drugs treating the inflammatory diseases. Am. J. Transl Res. 13, 391\u2013419 (2021).","journal-title":"Am. J. Transl Res."},{"key":"33453_CR15","doi-asserted-by":"publisher","first-page":"105977","DOI":"10.1016\/j.phrs.2021.105977","volume":"175","author":"YY Zhang","year":"2022","unstructured":"Zhang, Y. Y. et al. Microsomal prostaglandin E 2 synthase-1 and its inhibitors: molecular mechanisms and therapeutic significance. Pharmacol. Res. 175, 105977 (2022).","journal-title":"Pharmacol. Res."},{"key":"33453_CR16","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.4155\/fmc.11.136","volume":"3","author":"HH Chang","year":"2011","unstructured":"Chang, H. H. & Meuillet, E. J. Identification and development of mPGES-1 inhibitors: where we are at? Future Med. Chem. 3, 1909\u20131934 (2011).","journal-title":"Future Med. Chem."},{"key":"33453_CR17","doi-asserted-by":"publisher","first-page":"13966","DOI":"10.1096\/fj.201901460RR","volume":"33","author":"ELB Soldner","year":"2019","unstructured":"Soldner, E. L. B. et al. Inhibition of human microsomal PGE2 synthase-1 reduces seizure-induced increases of P-glycoprotein expression and activity at the blood-brain barrier. FASEB J. 33, 13966\u201313981 (2019).","journal-title":"FASEB J."},{"key":"33453_CR18","doi-asserted-by":"publisher","unstructured":"Edenius, E. G. et al. June. Inhibition of microsomal prostaglandin e synthase-1 (mpges-1) by GS-248 reduces prostaglandin e2 biosynthesis while increasing prostacyclin in human subjects. Ann Rheum Dis: first published as (2020). https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.5503 on 2.","DOI":"10.1136\/annrheumdis-2020-eular.5503"},{"key":"33453_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12967-021-03016-9","volume":"19","author":"M Gurusamy","year":"2021","unstructured":"Gurusamy, M. et al. Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice. J. Transl Med. 19, 340 (2021).","journal-title":"J. Transl Med."},{"key":"33453_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.prostaglandins.2009.06.006","volume":"90","author":"D Wu","year":"2009","unstructured":"Wu, D. et al. Comparison of microsomal prostaglandin E synthase-1 deletion and COX-2 Inhibition in acute cardiac ischemia in mice. Prostaglandins Other Lipid Mediat. 90, 21\u201325 (2009).","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"33453_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.plefa.2009.05.019","volume":"81","author":"D Wu","year":"2009","unstructured":"Wu, D. et al. The effects of microsomal prostaglandin E synthase-1 deletion in acute cardiac ischemia in mice. Prostaglandins Leukot. Essent. Fat. Acids. 81, 31\u201333 (2009).","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"33453_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.trsl.2018.07.010","volume":"203","author":"AS Ambade","year":"2019","unstructured":"Ambade, A. S., Jung, B., Lee, D., Doods, H. & Wu, D. Triple-tyrosine kinase Inhibition attenuates pulmonary arterial hypertension and neointimal formation. Transl Res. 203, 15\u201330 (2019).","journal-title":"Transl Res."},{"key":"33453_CR23","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1161\/HYPERTENSIONAHA.115.05338","volume":"66","author":"P Murugesan","year":"2015","unstructured":"Murugesan, P. et al. Inhibition of Kinin B1 receptors attenuates pulmonary hypertension and vascular remodeling. Hypertension 66, 906\u2013912 (2015).","journal-title":"Hypertension"},{"key":"33453_CR24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1161\/01.RES.73.5.792","volume":"73","author":"V Lindner","year":"1993","unstructured":"Lindner, V., Fingerle, J. & Reidy, M. A. Mouse model of arterial injury. Circ. Res. 73, 792\u2013796 (1993).","journal-title":"Circ. Res."},{"key":"33453_CR25","doi-asserted-by":"publisher","first-page":"32775","DOI":"10.1074\/jbc.M003504200","volume":"275","author":"T Tanioka","year":"2000","unstructured":"Tanioka, T., Nakatani, Y., Semmyo, N., Murakami, M. & Kudo, I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J. Biol. Chem. 275, 32775\u201332782 (2000).","journal-title":"J. Biol. Chem."},{"key":"33453_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1161\/hy02t2.102808","volume":"39","author":"M Mendez","year":"2002","unstructured":"Mendez, M. & LaPointe, M. C. Trophic effects of the cyclooxygenase-2 product prostaglandin E(2) in cardiac myocytes. Hypertension 39, 382\u2013388 (2002).","journal-title":"Hypertension"},{"key":"33453_CR27","doi-asserted-by":"publisher","first-page":"37937","DOI":"10.1074\/jbc.M305108200","volume":"278","author":"M Murakami","year":"2003","unstructured":"Murakami, M. et al. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and \u2013\u20092. J. Biol. Chem. 278, 37937\u201337947 (2003).","journal-title":"J. Biol. Chem."},{"key":"33453_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1124\/jpet.118.256057","volume":"370","author":"L Chen","year":"2019","unstructured":"Chen, L. et al. Myeloid cell mPges-1 deletion attenuates mortality without affecting remodeling after acute myocardial infarction in mice. J. Pharmacol. Exp. Ther. 370, 18\u201324 (2019).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"33453_CR29","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1161\/CIRCULATIONAHA.107.749739","volume":"117","author":"N Degousee","year":"2008","unstructured":"Degousee, N. et al. Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 117, 1701\u20131710 (2008).","journal-title":"Circulation"},{"key":"33453_CR30","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1111\/bph.16061","volume":"180","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Microsomal prostaglandin E synthase-1 Inhibition prevents adverse cardiac remodelling after myocardial infarction in mice. Br. J. Pharmacol. 180, 1981\u20131998 (2023).","journal-title":"Br. J. Pharmacol."},{"key":"33453_CR31","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2174\/0929867043365279","volume":"11","author":"X de Leval","year":"2004","unstructured":"de Leval, X. et al. New developments on thromboxane and Prostacyclin modulators part II: Prostacyclin modulators. Curr. Med. Chem. 11, 1243\u20131252 (2004).","journal-title":"Curr. Med. Chem."},{"key":"33453_CR32","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1161\/01.CIR.0000034733.93020.BC","volume":"106","author":"C Yokoyama","year":"2002","unstructured":"Yokoyama, C. et al. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 106, 2397\u20132403 (2002).","journal-title":"Circulation"},{"key":"33453_CR33","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/rheumatology\/keae049","volume":"64","author":"G Tornling","year":"2025","unstructured":"Tornling, G. et al. A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor Vipoglanstat in systemic sclerosis-related raynaud\u2019s. Rheumatol. (Oxford). 64, 704\u2013713 (2025).","journal-title":"Rheumatol. (Oxford)"},{"key":"33453_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/187152911795945169","volume":"11","author":"ER O\u2019 Brien","year":"2011","unstructured":"O\u2019 Brien, E. R., Ma, X., Simard, T., Pourdjabbar, A. & Hibbert, B. Pathogenesis of Neointima formation following vascular injury. Cardiovasc. Hematol. Disord Drug Targets. 11, 30\u201339 (2011).","journal-title":"Cardiovasc. Hematol. Disord Drug Targets"},{"key":"33453_CR35","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/cvr\/cvs276","volume":"96","author":"SA Goel","year":"2012","unstructured":"Goel, S. A., Guo, L. W., Liu, B. & Kent, K. C. Mechanisms of post-intervention arterial remodelling. Cardiovasc. Res. 96, 363\u2013371 (2012).","journal-title":"Cardiovasc. Res."},{"key":"33453_CR36","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1253\/circj.CJ-12-0801","volume":"76","author":"DI Simon","year":"2012","unstructured":"Simon, D. I. Inflammation and vascular injury: basic discovery to drug development. Circ. J. 76, 1811\u20131818 (2012).","journal-title":"Circ. J."},{"key":"33453_CR37","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2165\/00003495-200767090-00001","volume":"67","author":"V Ferrero","year":"2007","unstructured":"Ferrero, V., Ribichini, F., Pesarini, G., Brunelleschi, S. & Vassanelli, C. Glucocorticoids in the prevention of restenosis after coronary angioplasty: therapeutic potential. Drugs 67, 1243\u20131255 (2007).","journal-title":"Drugs"},{"key":"33453_CR38","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1161\/01.CIR.103.24.3019","volume":"103","author":"SC Smith Jr","year":"2001","unstructured":"Smith, S. C. Jr et al. ACC\/AHA guidelines for percutaneous coronary intervention. Circulation 103, 3019\u20133041 (2001).","journal-title":"Circulation"},{"key":"33453_CR39","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1161\/01.CIR.0000135467.43430.16","volume":"110","author":"HM Yang","year":"2004","unstructured":"Yang, H. M. et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through Inhibition of Akt signaling. Circulation 110, 301\u2013308 (2004).","journal-title":"Circulation"},{"key":"33453_CR40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/00005344-200501000-00011","volume":"45","author":"K Wang","year":"2005","unstructured":"Wang, K. et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. J. Cardiovasc. Pharmacol. 45, 61\u201367 (2005).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"33453_CR41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0140-6736(07)61295-1","volume":"370","author":"BK Koo","year":"2007","unstructured":"Koo, B. K. et al. Effect of celecoxib on restenosis after coronary angioplasty with a taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. Lancet 370, 567\u2013574 (2007).","journal-title":"Lancet"},{"key":"33453_CR42","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1126\/science.1068711","volume":"296","author":"Y Cheng","year":"2002","unstructured":"Cheng, Y. et al. Role of Prostacyclin in the cardiovascular response to thromboxane A2. Science 296, 539\u2013541 (2002).","journal-title":"Science"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33453-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33453-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33453-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:08:34Z","timestamp":1777388914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33453-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["33453"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-33453-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.W. was a former employee (1996\u20131999) and consultant of BI and has continued to collaborate with Boehringer Ingelheim. A.P. is an employee of Boehringer Ingelheim. This does not alter the authors\u2019 adherence to all the Journal policies on sharing data and materials. The remaining authors have disclosed that they do not have any conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Animal studies were performed according to national and institutional animal care and ethical guidelines and was approved by the local board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"44635"}}